RPRX NASDAQ
Royalty Pharma plc
1W: +7.5%
1M: +11.2%
3M: +8.0%
YTD: +67.5%
1Y: +76.7%
3Y: +145.3%
5Y: +94.0%
$65.31
+0.56 (+0.86%)
After Hours: $65.55 (+0.23, +0.36%)
Weekly Expected Move ±3.7%
$59
$62
$64
$66
$69
Credit Risk of going bust: lower than 80% of companies Debt: 23.7% of company value Bonds: $344.1M held by 346 funds, 85 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.07 (down 98%), Royalty Pharma plc would be worth roughly what it owes.
Total debt $8.96B against a stock market value of $28.84B.
Distance to default 9.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.67B (short-term plus half of long-term), stock volatility 23.6%; Altman Z'' 1.76. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.07 (down 98%), Royalty Pharma plc would be worth roughly what it owes.
Total debt $8.96B against a stock market value of $28.84B.
Distance to default 9.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.67B (short-term plus half of long-term), stock volatility 23.6%; Altman Z'' 1.76. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$28.8B
52W Range35.915-65.35
Volume4,108,042
Avg Volume3,115,225
Beta0.41
Dividend$0.93
Analyst Ratings
Company Info
CEOPablo Legorreta
Employees100
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2020-06-16
Websiteroyaltypharma.com
110 East 59th Street
New York, NY 10022
US
New York, NY 10022
US
212 883 0200
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest News
Brookstone Capital Management Buys 35,375 Shares of Royalty Pharma PLC $RPRX
Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
Goldman's defensive stocks with quality-growth characteristics
Royalty Pharma declares $0.235 dividend
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Urist Marshall | S-Sale | 4,126 | $57.10 | 2026-10-05 |
| Bassler Bonnie L | A-Award | 642 | $58.41 | 2026-09-30 |
| Urist Marshall | S-Sale | 4,126 | $57.88 | 2026-09-28 |
| Hite Christopher | S-Sale | 96,073 | $58.51 | 2026-09-22 |
| Hite Christopher | S-Sale | 3,927 | $58.93 | 2026-09-22 |